M&A/Joint Venture | Fangda Partners

Mylan in its combination with Upjohn, Pfizer’s off-patent branded and generic established medicine business, creating a new global pharmaceutical company.
Eddingpharm on its acquisition of two antibiotic products sold by Eli Lilly in China, Ceclor and Vanocin, as well as its Ceclor manufacturing facility in Suzhou with a total transaction value of US$375 million.
WuXi AppTec in its establishment of a joint venture with Mayo Clinic, a non-profit worldwide leader in medical care, research and education.
China Everbright on its acquisition of 22.4% of the shares in LifeTech, a leading cardiovascular device manufacture in China listed on the Hong Kong Stock Exchange for US$126 million.
Bluesail Medical Co. on its acquisition of 93.37% of the shares in Biosensors International, a medical device company established in Bermuda, for RMB5.9 billion.
Bayer on its acquisition of Dihon Pharmaceutical Group for about RMB3.6 billion. This deal was recognized as Deal of the Year 2015 by China Business Law Journal.
Bayer HealthCare China in its integration with the onshore part of Merck OTC Business, following Bayer’s global acquisition of Merck OTC department.
Yunfeng Capital and Alibaba Group in the privatization of iKang Healthcare Group, Inc., a leading health inspection chain in China, from NASDAQ.
Centurium Capital and other investors in the proposed privatization of China Biologic Products Holdings Inc., a leading fully integrated plasma-based biopharmaceutical company in China, from NASDAQ.